Abstract
{sup 99m}Tc-3PRGD{sub 2} is a new SPECT radiotracer for several tumor imaging with high uptake where integrin α{sub v}β{sub 3} is highly expressed. This pilot study was to assess the safety, biodistribution and radiation dosimetry of {sup 99m}Tc-3PRGD{sub 2} in healthy volunteers. The 10 healthy male volunteers were injected with {sup 99m}Tc-3PRGD{sub 2} (786.7±55.8 MBq, 19.1-24.2 mCi). Baseline measurements of vital signs, laboratory safety tests and 12-lead electrocardiogram were recorded before and after injection. Blood and urine samples were collected and radiation counts were obtained at various time points. Whole-body scans and ROIs of identified organs were used for visual analysis and estimating the radiation dosimetry. No adverse reactions were found during the study. {sup 99m}Tc-3PRGD{sub 2} exhibited a rapid clearance from the blood with less than 45% of the initial dosage at 10 min after injection and gradual increasing radioactivity in urine with (52.9±6)% of original dose at 1440 min. The whole-body imaging showed high radioactive accumulation in bladder. And the highest {sup 99m}Tc-3PRGD{sub 2} uptake was found in the kidneys (3.50×10{sup -2} mSv/MBq). The {sup 99m}Tc-3PRGD{sub 2} exhibited good pharmacokinetic properties and little radiation burden. This study showed that {sup 99m}Tc-3PRGD{sub 2} would be a safe and attractive
More>>
Guanghui, Cheng;
Shi, Gao;
Tiefeng, JI;
Qingjie, Ma;
Qing, Wang;
[1]
Bing, Jia;
[2]
Zuowei, Chen
[3]
- China-Japan Union Hospital, Jilin University, Changchun (China)
- Medical Isotopes Research Center, Peking University, Beijing (China)
- Department of Nuclear Medicine, People's Hospital of Shenzhen (China)
Citation Formats
Guanghui, Cheng, Shi, Gao, Tiefeng, JI, Qingjie, Ma, Qing, Wang, Bing, Jia, and Zuowei, Chen.
Pharmacokinetics and radiation dosimetry of {sup 99m}Tc-3PRGD{sub 2} in healthy individuals: A pilot study.
China: N. p.,
2012.
Web.
Guanghui, Cheng, Shi, Gao, Tiefeng, JI, Qingjie, Ma, Qing, Wang, Bing, Jia, & Zuowei, Chen.
Pharmacokinetics and radiation dosimetry of {sup 99m}Tc-3PRGD{sub 2} in healthy individuals: A pilot study.
China.
Guanghui, Cheng, Shi, Gao, Tiefeng, JI, Qingjie, Ma, Qing, Wang, Bing, Jia, and Zuowei, Chen.
2012.
"Pharmacokinetics and radiation dosimetry of {sup 99m}Tc-3PRGD{sub 2} in healthy individuals: A pilot study."
China.
@misc{etde_22501461,
title = {Pharmacokinetics and radiation dosimetry of {sup 99m}Tc-3PRGD{sub 2} in healthy individuals: A pilot study}
author = {Guanghui, Cheng, Shi, Gao, Tiefeng, JI, Qingjie, Ma, Qing, Wang, Bing, Jia, and Zuowei, Chen}
abstractNote = {{sup 99m}Tc-3PRGD{sub 2} is a new SPECT radiotracer for several tumor imaging with high uptake where integrin α{sub v}β{sub 3} is highly expressed. This pilot study was to assess the safety, biodistribution and radiation dosimetry of {sup 99m}Tc-3PRGD{sub 2} in healthy volunteers. The 10 healthy male volunteers were injected with {sup 99m}Tc-3PRGD{sub 2} (786.7±55.8 MBq, 19.1-24.2 mCi). Baseline measurements of vital signs, laboratory safety tests and 12-lead electrocardiogram were recorded before and after injection. Blood and urine samples were collected and radiation counts were obtained at various time points. Whole-body scans and ROIs of identified organs were used for visual analysis and estimating the radiation dosimetry. No adverse reactions were found during the study. {sup 99m}Tc-3PRGD{sub 2} exhibited a rapid clearance from the blood with less than 45% of the initial dosage at 10 min after injection and gradual increasing radioactivity in urine with (52.9±6)% of original dose at 1440 min. The whole-body imaging showed high radioactive accumulation in bladder. And the highest {sup 99m}Tc-3PRGD{sub 2} uptake was found in the kidneys (3.50×10{sup -2} mSv/MBq). The {sup 99m}Tc-3PRGD{sub 2} exhibited good pharmacokinetic properties and little radiation burden. This study showed that {sup 99m}Tc-3PRGD{sub 2} would be a safe and attractive SPECT agent in clinic applications. (authors)}
journal = []
issue = {6}
volume = {23}
journal type = {AC}
place = {China}
year = {2012}
month = {Dec}
}
title = {Pharmacokinetics and radiation dosimetry of {sup 99m}Tc-3PRGD{sub 2} in healthy individuals: A pilot study}
author = {Guanghui, Cheng, Shi, Gao, Tiefeng, JI, Qingjie, Ma, Qing, Wang, Bing, Jia, and Zuowei, Chen}
abstractNote = {{sup 99m}Tc-3PRGD{sub 2} is a new SPECT radiotracer for several tumor imaging with high uptake where integrin α{sub v}β{sub 3} is highly expressed. This pilot study was to assess the safety, biodistribution and radiation dosimetry of {sup 99m}Tc-3PRGD{sub 2} in healthy volunteers. The 10 healthy male volunteers were injected with {sup 99m}Tc-3PRGD{sub 2} (786.7±55.8 MBq, 19.1-24.2 mCi). Baseline measurements of vital signs, laboratory safety tests and 12-lead electrocardiogram were recorded before and after injection. Blood and urine samples were collected and radiation counts were obtained at various time points. Whole-body scans and ROIs of identified organs were used for visual analysis and estimating the radiation dosimetry. No adverse reactions were found during the study. {sup 99m}Tc-3PRGD{sub 2} exhibited a rapid clearance from the blood with less than 45% of the initial dosage at 10 min after injection and gradual increasing radioactivity in urine with (52.9±6)% of original dose at 1440 min. The whole-body imaging showed high radioactive accumulation in bladder. And the highest {sup 99m}Tc-3PRGD{sub 2} uptake was found in the kidneys (3.50×10{sup -2} mSv/MBq). The {sup 99m}Tc-3PRGD{sub 2} exhibited good pharmacokinetic properties and little radiation burden. This study showed that {sup 99m}Tc-3PRGD{sub 2} would be a safe and attractive SPECT agent in clinic applications. (authors)}
journal = []
issue = {6}
volume = {23}
journal type = {AC}
place = {China}
year = {2012}
month = {Dec}
}